Adimab, LLC, a global leader in the discovery of human antibodies, today reported the isolation of a broad panel of neutralizing anti-Ebola virus antibodies from a survivor of the recent Zaire outbreak. The work, published online today in the journal Science, highlights the remarkable speed of Adimab’s recently launched single B cell isolation platform, and constitutes the largest panel of functional anti-Ebola antibodies reported in the scientific literature to date. The sequences of all antibodies isolated in this study will be made freely available to the research community through the GenBank database.